Owkin collaborates with Amazon Web Services (AWS) to leverage cloud infrastructure and advanced AI tools for accelerating innovation in precision medicine. The partnership aims to streamline research operations and drive key initiatives in drug discovery and clinical trials.
Owkin Collaborates with AWS to Advance Precision Medicine Using Generative AI
Owkin, a company specializing in precision medicine, announced its collaboration with Amazon Web Services (AWS) to enhance drug discovery, streamline clinical trials, and develop AI diagnostics. Owkin will utilize AWS’s secure and scalable cloud platform to manage extensive data operations and drive key research initiatives. This partnership aims to integrate Owkin’s biotech research with AWS’s cloud infrastructure to accelerate innovation in precision medicine.
Thomas Clozel, cofounder and CEO of Owkin, emphasized the importance of extracting insights from large datasets in hospitals and research centers efficiently and securely. The collaboration with AWS will enable Owkin to leverage high-performance computing and machine learning tools, including Amazon SageMaker, for developing and deploying AI models.
The initiative expects to use AWS’s infrastructure, such as Amazon EC2 UltraClusters powered by NVIDIA H100 Tensor Core GPUs, to significantly reduce the time required to train machine learning models. Moreover, Owkin plans to explore AWS’s specialized chips, AWS Trainium and AWS Graviton, for enhanced performance.
AWS’s comprehensive compliance controls will support Owkin in meeting global regulatory requirements, ensuring data security and sovereignty. Dan Sheeran, General Manager of Healthcare and Life Sciences at AWS, underlined the potential of generative AI to make breakthroughs in healthcare while lowering costs and improving treatment precision.
